ViCentra Expands Financing to $98 Million to Accelerate European Commercialization and Ready Next Generation Kaleido Insulin Patch Pump System for U.S. Access
- Secures an additional $13 million, bringing the total to $98 million with new investments from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech, plus increased support from Innovation Industries
- Strengthens manufacturing scale-up and commercial operations in Germany, the Netherlands, and France, and advances U.S. market preparation
- Validates ViCentra’s strategy and team, following a year of significant commercial and operational milestones
__________________________________________________________________________________
Utrecht, the Netherlands — January 8, 2026
ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, today announced the second close of its Series D financing round, adding $13 million and increasing the total round to $98 million. The additional funding follows a strong year of commercial and operational progress and includes new capital from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech, alongside increased support from existing investor Innovation Industries. With this funding, ViCentra will scale manufacturing, deepen commercial execution in Germany, the Netherlands, and France, and accelerate preparations for its next-generation Kaleido insulin patch pump for U.S. market access.
